"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","treatment_protocol_ch1","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count"
"GSM405556","Ovarian tumor sample 169","GSM405556","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 62","status: 1","fumnd: 7","age: 61","sample nr: 258","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405556/GSM405556.xls.gz","37632"
"GSM405557","Ovarian tumor sample 390","GSM405557","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 151","status: 1","fumnd: 13","age: 51","sample nr: 104","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405557/GSM405557.xls.gz","37632"
"GSM405558","Ovarian tumor sample 70","GSM405558","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 34","status: 0","fumnd: 122","age: 42","sample nr: 463","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405558/GSM405558.xls.gz","37632"
"GSM405559","Ovarian tumor sample 171","GSM405559","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 106","status: 1","fumnd: 12","age: 49","sample nr: 429","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405559/GSM405559.xls.gz","37632"
"GSM405560","Ovarian tumor sample 326","GSM405560","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 131","status: 1","fumnd: 33","age: 58","sample nr: 109","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405560/GSM405560.xls.gz","37632"
"GSM405561","Ovarian tumor sample 256","GSM405561","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 111","status: 1","fumnd: 59","age: 61","sample nr: 111","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405561/GSM405561.xls.gz","37632"
"GSM405562","Ovarian tumor sample 198","GSM405562","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 3","status: 1","fumnd: 47","age: 55","sample nr: 413","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405562/GSM405562.xls.gz","37632"
"GSM405563","Ovarian tumor sample 300","GSM405563","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 122","status: 1","fumnd: 50","age: 53","sample nr: 112","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405563/GSM405563.xls.gz","37632"
"GSM405564","Ovarian tumor sample 404","GSM405564","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 155","status: 0","fumnd: 62","age: 48","sample nr: 113","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405564/GSM405564.xls.gz","37632"
"GSM405565","Ovarian tumor sample 370","GSM405565","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 145","status: 1","fumnd: 23","age: 61","sample nr: 115","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405565/GSM405565.xls.gz","37632"
"GSM405566","Ovarian tumor sample 191","GSM405566","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 69","status: 1","fumnd: 8","age: 54","sample nr: 176","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405566/GSM405566.xls.gz","37632"
"GSM405567","Ovarian tumor sample 304","GSM405567","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 123","status: 1","fumnd: 59","age: 42","sample nr: 116","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405567/GSM405567.xls.gz","37632"
"GSM405568","Ovarian tumor sample 137","GSM405568","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 100","status: 1","fumnd: 18","age: 62","sample nr: 61","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405568/GSM405568.xls.gz","37632"
"GSM405569","Ovarian tumor sample 141","GSM405569","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 102","status: 0","fumnd: 132","age: 65","sample nr: 117","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405569/GSM405569.xls.gz","37632"
"GSM405570","Ovarian tumor sample 230","GSM405570","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 9","status: 1","fumnd: 18","age: 42","sample nr: 336","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405570/GSM405570.xls.gz","37632"
"GSM405571","Ovarian tumor sample 231","GSM405571","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 9","status: 1","fumnd: 18","age: 42","sample nr: 336","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405571/GSM405571.xls.gz","37632"
"GSM405572","Ovarian tumor sample 381","GSM405572","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 149","status: 0","fumnd: 116","age: 54","sample nr: 332","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405572/GSM405572.xls.gz","37632"
"GSM405573","Ovarian tumor sample 388","GSM405573","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 150","status: 1","fumnd: 16","age: 44","sample nr: 333","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405573/GSM405573.xls.gz","37632"
"GSM405574","Ovarian tumor sample 352","GSM405574","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 139","status: 1","fumnd: 29","age: 56","sample nr: 224","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405574/GSM405574.xls.gz","37632"
"GSM405575","Ovarian tumor sample 74","GSM405575","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 94","status: 1","fumnd: 167","age: 31","sample nr: 129","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405575/GSM405575.xls.gz","37632"
"GSM405576","Ovarian tumor sample 63","GSM405576","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 92","status: 0","fumnd: 20","age: 45","sample nr: 56","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405576/GSM405576.xls.gz","37632"
"GSM405577","Ovarian tumor sample 98","GSM405577","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 99","status: 0","fumnd: 14","age: 65","sample nr: 130","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405577/GSM405577.xls.gz","37632"
"GSM405578","Ovarian tumor sample 13","GSM405578","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 85","status: 1","fumnd: 25","age: 51","sample nr: 248","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405578/GSM405578.xls.gz","37632"
"GSM405579","Ovarian tumor sample 273","GSM405579","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 115","status: 1","fumnd: 14","age: 60","sample nr: 131","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405579/GSM405579.xls.gz","37632"
"GSM405580","Ovarian tumor sample 14","GSM405580","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 85","status: 1","fumnd: 25","age: 51","sample nr: 248","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405580/GSM405580.xls.gz","37632"
"GSM405581","Ovarian tumor sample 274","GSM405581","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 115","status: 1","fumnd: 14","age: 60","sample nr: 131","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405581/GSM405581.xls.gz","37632"
"GSM405582","Ovarian tumor sample 296","GSM405582","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 121","status: 1","fumnd: 16","age: 48","sample nr: 253","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405582/GSM405582.xls.gz","37632"
"GSM405583","Ovarian tumor sample 200","GSM405583","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 71","status: 1","fumnd: 13","age: 43","sample nr: 133","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405583/GSM405583.xls.gz","37632"
"GSM405584","Ovarian tumor sample 208","GSM405584","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 72","status: 1","fumnd: 18","age: 53","sample nr: 223","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405584/GSM405584.xls.gz","37632"
"GSM405585","Ovarian tumor sample 348","GSM405585","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 81","status: 1","fumnd: 12","age: 52","sample nr: 134","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405585/GSM405585.xls.gz","37632"
"GSM405586","Ovarian tumor sample 254","GSM405586","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 78","status: 0","fumnd: 14","age: 59","sample nr: 191","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405586/GSM405586.xls.gz","37632"
"GSM405587","Ovarian tumor sample 96","GSM405587","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 98","status: 0","fumnd: 21","age: 47","sample nr: 136","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405587/GSM405587.xls.gz","37632"
"GSM405588","Ovarian tumor sample 90","GSM405588","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 95","status: 0","fumnd: 6","age: 71","sample nr: 63","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405588/GSM405588.xls.gz","37632"
"GSM405589","Ovarian tumor sample 400","GSM405589","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 154","status: 1","fumnd: 21","age: 55","sample nr: 384","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405589/GSM405589.xls.gz","37632"
"GSM405590","Ovarian tumor sample 15","GSM405590","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 85","status: 1","fumnd: 25","age: 51","sample nr: 296","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405590/GSM405590.xls.gz","37632"
"GSM405591","Ovarian tumor sample 180","GSM405591","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 65","status: 1","fumnd: 70","age: 61","sample nr: 214","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405591/GSM405591.xls.gz","37632"
"GSM405592","Ovarian tumor sample 267","GSM405592","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 113","status: 1","fumnd: 31","age: 62","sample nr: 266","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405592/GSM405592.xls.gz","37632"
"GSM405593","Ovarian tumor sample 201","GSM405593","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 71","status: 1","fumnd: 13","age: 43","sample nr: 133","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405593/GSM405593.xls.gz","37632"
"GSM405594","Ovarian tumor sample 378","GSM405594","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 148","status: 1","fumnd: 10","age: 61","sample nr: 9","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405594/GSM405594.xls.gz","37632"
"GSM405595","Ovarian tumor sample 344","GSM405595","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 137","status: 1","fumnd: 30","age: 50","sample nr: 15","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405595/GSM405595.xls.gz","37632"
"GSM405596","Ovarian tumor sample 379","GSM405596","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 148","status: 1","fumnd: 10","age: 61","sample nr: 9","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405596/GSM405596.xls.gz","37632"
"GSM405597","Ovarian tumor sample 131","GSM405597","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 51","status: 1","fumnd: 8","age: 57","sample nr: 160","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405597/GSM405597.xls.gz","37632"
"GSM405598","Ovarian tumor sample 111","GSM405598","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 45","status: 0","fumnd: 64","age: 66","sample nr: 343","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405598/GSM405598.xls.gz","37632"
"GSM405599","Ovarian tumor sample 112","GSM405599","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 45","status: 0","fumnd: 64","age: 66","sample nr: 343","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405599/GSM405599.xls.gz","37632"
"GSM405600","Ovarian tumor sample 119","GSM405600","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 47","status: 1","fumnd: 33","age: 43","sample nr: 379","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405600/GSM405600.xls.gz","37632"
"GSM405601","Ovarian tumor sample 142","GSM405601","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 102","status: 0","fumnd: 132","age: 65","sample nr: 117","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405601/GSM405601.xls.gz","37632"
"GSM405602","Ovarian tumor sample 84","GSM405602","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 39","status: 1","fumnd: 5","age: 76","sample nr: 165","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405602/GSM405602.xls.gz","37632"
"GSM405603","Ovarian tumor sample 196","GSM405603","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 2","status: 1","fumnd: 1","age: 64","sample nr: 457","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405603/GSM405603.xls.gz","37632"
"GSM405604","Ovarian tumor sample 34","GSM405604","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 28","status: 1","fumnd: 42","age: 68","sample nr: 425","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405604/GSM405604.xls.gz","37632"
"GSM405605","Ovarian tumor sample 309","GSM405605","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 125","status: 0","fumnd: 71","age: 66","sample nr: 167","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405605/GSM405605.xls.gz","37632"
"GSM405606","Ovarian tumor sample 265","GSM405606","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 112","status: 0","fumnd: 92","age: 51","sample nr: 168","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405606/GSM405606.xls.gz","37632"
"GSM405607","Ovarian tumor sample 94","GSM405607","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 97","status: 1","fumnd: 9","age: 74","sample nr: 482","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405607/GSM405607.xls.gz","37632"
"GSM405608","Ovarian tumor sample 103","GSM405608","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 42","status: 1","fumnd: 2","age: 57","sample nr: 170","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405608/GSM405608.xls.gz","37632"
"GSM405609","Ovarian tumor sample 241","GSM405609","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 11","status: 1","fumnd: 5","age: 48","sample nr: 173","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405609/GSM405609.xls.gz","37632"
"GSM405610","Ovarian tumor sample 192","GSM405610","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 69","status: 1","fumnd: 8","age: 54","sample nr: 176","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405610/GSM405610.xls.gz","37632"
"GSM405611","Ovarian tumor sample 282","GSM405611","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 117","status: 0","fumnd: 213","age: 43","sample nr: 267","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405611/GSM405611.xls.gz","37632"
"GSM405612","Ovarian tumor sample 18","GSM405612","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 86","status: 1","fumnd: 9","age: 68","sample nr: 177","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405612/GSM405612.xls.gz","37632"
"GSM405613","Ovarian tumor sample 185","GSM405613","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 66","status: 1","fumnd: 10","age: 75","sample nr: 179","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405613/GSM405613.xls.gz","37632"
"GSM405614","Ovarian tumor sample 126","GSM405614","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 50","status: 1","fumnd: 18","age: 48","sample nr: 235","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405614/GSM405614.xls.gz","37632"
"GSM405615","Ovarian tumor sample 127","GSM405615","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 50","status: 1","fumnd: 18","age: 48","sample nr: 235","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405615/GSM405615.xls.gz","37632"
"GSM405616","Ovarian tumor sample 385","GSM405616","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 20","status: 1","fumnd: 46","age: 71","sample nr: 423","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405616/GSM405616.xls.gz","37632"
"GSM405617","Ovarian tumor sample 386","GSM405617","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 20","status: 1","fumnd: 46","age: 71","sample nr: 423","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405617/GSM405617.xls.gz","37632"
"GSM405618","Ovarian tumor sample 346","GSM405618","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 138","status: 1","fumnd: 12","age: 63","sample nr: 182","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405618/GSM405618.xls.gz","37632"
"GSM405619","Ovarian tumor sample 269","GSM405619","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 114","status: 1","fumnd: 24","age: 74","sample nr: 355","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405619/GSM405619.xls.gz","37632"
"GSM405620","Ovarian tumor sample 289","GSM405620","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 119","status: 1","fumnd: 12","age: 57","sample nr: 183","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405620/GSM405620.xls.gz","37632"
"GSM405621","Ovarian tumor sample 257","GSM405621","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 111","status: 1","fumnd: 59","age: 61","sample nr: 111","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405621/GSM405621.xls.gz","37632"
"GSM405622","Ovarian tumor sample 78","GSM405622","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 36","status: 1","fumnd: 12","age: 71","sample nr: 184","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405622/GSM405622.xls.gz","37632"
"GSM405623","Ovarian tumor sample 75","GSM405623","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 94","status: 1","fumnd: 167","age: 31","sample nr: 293","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405623/GSM405623.xls.gz","37632"
"GSM405624","Ovarian tumor sample 244","GSM405624","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 12","status: 1","fumnd: 21","age: 67","sample nr: 185","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405624/GSM405624.xls.gz","37632"
"GSM405625","Ovarian tumor sample 21","GSM405625","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 25","status: 0","fumnd: 31","age: 68","sample nr: 186","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405625/GSM405625.xls.gz","37632"
"GSM405626","Ovarian tumor sample 189","GSM405626","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 68","status: 1","fumnd: 30","age: 72","sample nr: 431","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405626/GSM405626.xls.gz","37632"
"GSM405627","Ovarian tumor sample 38","GSM405627","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 30","status: 0","fumnd: 62","age: 71","sample nr: 341","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405627/GSM405627.xls.gz","37632"
"GSM405628","Ovarian tumor sample 105","GSM405628","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 43","status: 0","fumnd: 59","age: 63","sample nr: 402","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405628/GSM405628.xls.gz","37632"
"GSM405629","Ovarian tumor sample 106","GSM405629","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 43","status: 0","fumnd: 59","age: 63","sample nr: 402","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405629/GSM405629.xls.gz","37632"
"GSM405630","Ovarian tumor sample 235","GSM405630","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 10","status: 0","fumnd: 80","age: 54","sample nr: 232","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405630/GSM405630.xls.gz","37632"
"GSM405631","Ovarian tumor sample 147","GSM405631","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 55","status: 1","fumnd: 12","age: 65","sample nr: 190","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405631/GSM405631.xls.gz","37632"
"GSM405632","Ovarian tumor sample 366","GSM405632","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 143","status: 1","fumnd: 32","age: 43","sample nr: 444","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405632/GSM405632.xls.gz","37632"
"GSM405633","Ovarian tumor sample 255","GSM405633","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 78","status: 0","fumnd: 14","age: 59","sample nr: 191","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405633/GSM405633.xls.gz","37632"
"GSM405634","Ovarian tumor sample 165","GSM405634","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 61","status: 0","fumnd: 67","age: 72","sample nr: 193","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405634/GSM405634.xls.gz","37632"
"GSM405635","Ovarian tumor sample 166","GSM405635","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 61","status: 0","fumnd: 67","age: 72","sample nr: 193","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405635/GSM405635.xls.gz","37632"
"GSM405636","Ovarian tumor sample 80","GSM405636","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 37","status: 1","fumnd: 68","age: 48","sample nr: 194","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405636/GSM405636.xls.gz","37632"
"GSM405637","Ovarian tumor sample 202","GSM405637","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 4","status: 1","fumnd: 22","age: 72","sample nr: 217","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405637/GSM405637.xls.gz","37632"
"GSM405638","Ovarian tumor sample 100","GSM405638","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 41","status: 0","fumnd: 25","age: 54","sample nr: 197","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405638/GSM405638.xls.gz","37632"
"GSM405639","Ovarian tumor sample 383","GSM405639","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 19","status: 1","fumnd: 14","age: 74","sample nr: 400","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405639/GSM405639.xls.gz","37632"
"GSM405640","Ovarian tumor sample 86","GSM405640","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 40","status: 0","fumnd: 29","age: 65","sample nr: 199","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405640/GSM405640.xls.gz","37632"
"GSM405641","Ovarian tumor sample 129","GSM405641","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 1","status: 1","fumnd: 41","age: 55","sample nr: 200","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405641/GSM405641.xls.gz","37632"
"GSM405642","Ovarian tumor sample 19","GSM405642","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 86","status: 1","fumnd: 9","age: 68","sample nr: 177","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405642/GSM405642.xls.gz","37632"
"GSM405643","Ovarian tumor sample 20","GSM405643","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 86","status: 1","fumnd: 9","age: 68","sample nr: 177","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405643/GSM405643.xls.gz","37632"
"GSM405644","Ovarian tumor sample 22","GSM405644","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 25","status: 0","fumnd: 31","age: 68","sample nr: 186","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405644/GSM405644.xls.gz","37632"
"GSM405645","Ovarian tumor sample 284","GSM405645","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 118","status: 1","fumnd: 43","age: 42","sample nr: 202","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405645/GSM405645.xls.gz","37632"
"GSM405646","Ovarian tumor sample 23","GSM405646","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 25","status: 0","fumnd: 31","age: 68","sample nr: 186","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405646/GSM405646.xls.gz","37632"
"GSM405647","Ovarian tumor sample 285","GSM405647","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 118","status: 1","fumnd: 43","age: 42","sample nr: 202","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405647/GSM405647.xls.gz","37632"
"GSM405648","Ovarian tumor sample 286","GSM405648","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 118","status: 1","fumnd: 43","age: 42","sample nr: 250","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405648/GSM405648.xls.gz","37632"
"GSM405649","Ovarian tumor sample 337","GSM405649","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 135","status: 1","fumnd: 15","age: 62","sample nr: 207","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405649/GSM405649.xls.gz","37632"
"GSM405650","Ovarian tumor sample 270","GSM405650","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 114","status: 1","fumnd: 24","age: 74","sample nr: 209","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405650/GSM405650.xls.gz","37632"
"GSM405651","Ovarian tumor sample 122","GSM405651","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 48","status: 0","fumnd: 73","age: 73","sample nr: 211","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405651/GSM405651.xls.gz","37632"
"GSM405652","Ovarian tumor sample 173","GSM405652","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 63","status: 1","fumnd: 16","age: 51","sample nr: 213","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405652/GSM405652.xls.gz","37632"
"GSM405653","Ovarian tumor sample 291","GSM405653","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 120","status: 1","fumnd: 37","age: 69","sample nr: 374","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405653/GSM405653.xls.gz","37632"
"GSM405654","Ovarian tumor sample 181","GSM405654","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 65","status: 1","fumnd: 70","age: 61","sample nr: 214","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405654/GSM405654.xls.gz","37632"
"GSM405655","Ovarian tumor sample 203","GSM405655","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 4","status: 1","fumnd: 22","age: 72","sample nr: 217","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405655/GSM405655.xls.gz","37632"
"GSM405656","Ovarian tumor sample 204","GSM405656","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 4","status: 1","fumnd: 22","age: 72","sample nr: 217","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405656/GSM405656.xls.gz","37632"
"GSM405657","Ovarian tumor sample 205","GSM405657","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 4","status: 1","fumnd: 22","age: 72","sample nr: 217","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405657/GSM405657.xls.gz","37632"
"GSM405658","Ovarian tumor sample 135","GSM405658","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 53","status: 1","fumnd: 66","age: 60","sample nr: 219","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405658/GSM405658.xls.gz","37632"
"GSM405659","Ovarian tumor sample 124","GSM405659","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 49","status: 1","fumnd: 30","age: 54","sample nr: 346","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405659/GSM405659.xls.gz","37632"
"GSM405660","Ovarian tumor sample 368","GSM405660","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 144","status: 1","fumnd: 37","age: 48","sample nr: 331","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405660/GSM405660.xls.gz","37632"
"GSM405661","Ovarian tumor sample 209","GSM405661","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 72","status: 1","fumnd: 18","age: 53","sample nr: 223","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405661/GSM405661.xls.gz","37632"
"GSM405662","Ovarian tumor sample 353","GSM405662","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 139","status: 1","fumnd: 29","age: 56","sample nr: 224","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405662/GSM405662.xls.gz","37632"
"GSM405663","Ovarian tumor sample 372","GSM405663","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 146","status: 1","fumnd: 9","age: 60","sample nr: 226","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405663/GSM405663.xls.gz","37632"
"GSM405664","Ovarian tumor sample 374","GSM405664","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 147","status: 1","fumnd: 9","age: 62","sample nr: 227","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405664/GSM405664.xls.gz","37632"
"GSM405665","Ovarian tumor sample 228","GSM405665","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 74","status: 1","fumnd: 12","age: 64","sample nr: 396","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405665/GSM405665.xls.gz","37632"
"GSM405666","Ovarian tumor sample 36","GSM405666","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 29","status: 1","fumnd: 16","age: 72","sample nr: 460","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405666/GSM405666.xls.gz","37632"
"GSM405667","Ovarian tumor sample 407","GSM405667","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 156","status: 0","fumnd: 77","age: 46","sample nr: 231","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405667/GSM405667.xls.gz","37632"
"GSM405668","Ovarian tumor sample 236","GSM405668","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 10","status: 0","fumnd: 80","age: 54","sample nr: 232","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405668/GSM405668.xls.gz","37632"
"GSM405669","Ovarian tumor sample 216","GSM405669","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 8","status: 1","fumnd: 12","age: 71","sample nr: 377","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405669/GSM405669.xls.gz","37632"
"GSM405670","Ovarian tumor sample 318","GSM405670","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 80","status: 1","fumnd: 47","age: 50","sample nr: 233","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405670/GSM405670.xls.gz","37632"
"GSM405671","Ovarian tumor sample 82","GSM405671","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 38","status: 0","fumnd: 14","age: 80","sample nr: 466","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405671/GSM405671.xls.gz","37632"
"GSM405672","Ovarian tumor sample 391","GSM405672","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 151","status: 1","fumnd: 13","age: 51","sample nr: 234","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405672/GSM405672.xls.gz","37632"
"GSM405673","Ovarian tumor sample 275","GSM405673","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 115","status: 1","fumnd: 14","age: 60","sample nr: 131","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405673/GSM405673.xls.gz","37632"
"GSM405674","Ovarian tumor sample 128","GSM405674","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 50","status: 1","fumnd: 18","age: 48","sample nr: 235","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405674/GSM405674.xls.gz","37632"
"GSM405675","Ovarian tumor sample 26","GSM405675","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 26","status: 1","fumnd: 61","age: 71","sample nr: 329","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405675/GSM405675.xls.gz","37632"
"GSM405676","Ovarian tumor sample 42","GSM405676","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 89","status: 1","fumnd: 11","age: 68","sample nr: 237","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405676/GSM405676.xls.gz","37632"
"GSM405677","Ovarian tumor sample 311","GSM405677","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 126","status: 0","fumnd: 29","age: 42","sample nr: 249","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405677/GSM405677.xls.gz","37632"
"GSM405678","Ovarian tumor sample 261","GSM405678","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 14","status: 1","fumnd: 9","age: 60","sample nr: 239","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405678/GSM405678.xls.gz","37632"
"GSM405679","Ovarian tumor sample 152","GSM405679","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 57","status: 1","fumnd: 20","age: 71","sample nr: 392","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405679/GSM405679.xls.gz","37632"
"GSM405680","Ovarian tumor sample 222","GSM405680","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 108","status: 1","fumnd: 22","age: 61","sample nr: 419","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405680/GSM405680.xls.gz","37632"
"GSM405681","Ovarian tumor sample 392","GSM405681","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 151","status: 1","fumnd: 13","age: 51","sample nr: 234","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405681/GSM405681.xls.gz","37632"
"GSM405682","Ovarian tumor sample 361","GSM405682","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 83","status: 0","fumnd: 43","age: 66","sample nr: 244","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405682/GSM405682.xls.gz","37632"
"GSM405683","Ovarian tumor sample 278","GSM405683","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 79","status: 1","fumnd: 16","age: 39","sample nr: 439","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405683/GSM405683.xls.gz","37632"
"GSM405684","Ovarian tumor sample 132","GSM405684","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 51","status: 1","fumnd: 8","age: 57","sample nr: 160","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405684/GSM405684.xls.gz","37632"
"GSM405685","Ovarian tumor sample 16","GSM405685","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 85","status: 1","fumnd: 25","age: 51","sample nr: 248","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405685/GSM405685.xls.gz","37632"
"GSM405686","Ovarian tumor sample 246","GSM405686","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 76","status: 1","fumnd: 2","age: 78","sample nr: 272","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405686/GSM405686.xls.gz","37632"
"GSM405687","Ovarian tumor sample 312","GSM405687","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 126","status: 0","fumnd: 29","age: 42","sample nr: 249","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405687/GSM405687.xls.gz","37632"
"GSM405688","Ovarian tumor sample 59","GSM405688","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 33","status: 1","fumnd: 30","age: 75","sample nr: 342","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405688/GSM405688.xls.gz","37632"
"GSM405689","Ovarian tumor sample 287","GSM405689","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 118","status: 1","fumnd: 43","age: 42","sample nr: 250","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405689/GSM405689.xls.gz","37632"
"GSM405690","Ovarian tumor sample 371","GSM405690","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 145","status: 1","fumnd: 23","age: 61","sample nr: 115","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405690/GSM405690.xls.gz","37632"
"GSM405691","Ovarian tumor sample 354","GSM405691","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 140","status: 0","fumnd: 124","age: 74","sample nr: 45","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405691/GSM405691.xls.gz","37632"
"GSM405692","Ovarian tumor sample 297","GSM405692","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 121","status: 1","fumnd: 16","age: 48","sample nr: 253","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405692/GSM405692.xls.gz","37632"
"GSM405693","Ovarian tumor sample 328","GSM405693","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 132","status: 1","fumnd: 16","age: 27","sample nr: 292","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405693/GSM405693.xls.gz","37632"
"GSM405694","Ovarian tumor sample 32","GSM405694","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 27","status: 0","fumnd: 29","age: 43","sample nr: 254","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405694/GSM405694.xls.gz","37632"
"GSM405695","Ovarian tumor sample 170","GSM405695","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 62","status: 1","fumnd: 7","age: 61","sample nr: 258","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405695/GSM405695.xls.gz","37632"
"GSM405696","Ovarian tumor sample 258","GSM405696","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 13","status: 1","fumnd: 19","age: 41","sample nr: 259","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405696/GSM405696.xls.gz","37632"
"GSM405697","Ovarian tumor sample 259","GSM405697","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 13","status: 1","fumnd: 19","age: 41","sample nr: 259","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405697/GSM405697.xls.gz","37632"
"GSM405698","Ovarian tumor sample 3","GSM405698","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 22","status: 0","fumnd: 65","age: 63","sample nr: 261","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405698/GSM405698.xls.gz","37632"
"GSM405699","Ovarian tumor sample 212","GSM405699","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 7","status: 1","fumnd: 17","age: 72","sample nr: 262","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405699/GSM405699.xls.gz","37632"
"GSM405700","Ovarian tumor sample 108","GSM405700","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 44","status: 1","fumnd: 16","age: 66","sample nr: 5","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405700/GSM405700.xls.gz","37632"
"GSM405701","Ovarian tumor sample 157","GSM405701","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 59","status: 1","fumnd: 2","age: 45","sample nr: 263","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405701/GSM405701.xls.gz","37632"
"GSM405702","Ovarian tumor sample 355","GSM405702","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 140","status: 0","fumnd: 124","age: 74","sample nr: 48","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405702/GSM405702.xls.gz","37632"
"GSM405703","Ovarian tumor sample 268","GSM405703","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 113","status: 1","fumnd: 31","age: 62","sample nr: 266","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405703/GSM405703.xls.gz","37632"
"GSM405704","Ovarian tumor sample 283","GSM405704","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 117","status: 0","fumnd: 213","age: 43","sample nr: 267","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405704/GSM405704.xls.gz","37632"
"GSM405705","Ovarian tumor sample 339","GSM405705","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 18","status: 0","fumnd: 136","age: 60","sample nr: 415","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405705/GSM405705.xls.gz","37632"
"GSM405706","Ovarian tumor sample 340","GSM405706","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 18","status: 0","fumnd: 136","age: 60","sample nr: 415","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405706/GSM405706.xls.gz","37632"
"GSM405707","Ovarian tumor sample 24","GSM405707","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 87","status: 1","fumnd: 19","age: 66","sample nr: 67","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405707/GSM405707.xls.gz","37632"
"GSM405708","Ovarian tumor sample 247","GSM405708","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 76","status: 1","fumnd: 2","age: 78","sample nr: 272","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405708/GSM405708.xls.gz","37632"
"GSM405709","Ovarian tumor sample 87","GSM405709","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 40","status: 0","fumnd: 29","age: 65","sample nr: 199","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405709/GSM405709.xls.gz","37632"
"GSM405710","Ovarian tumor sample 88","GSM405710","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 40","status: 0","fumnd: 29","age: 65","sample nr: 199","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405710/GSM405710.xls.gz","37632"
"GSM405711","Ovarian tumor sample 89","GSM405711","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 40","status: 0","fumnd: 29","age: 65","sample nr: 199","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405711/GSM405711.xls.gz","37632"
"GSM405712","Ovarian tumor sample 45","GSM405712","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 31","status: 1","fumnd: 10","age: 84","sample nr: 363","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405712/GSM405712.xls.gz","37632"
"GSM405713","Ovarian tumor sample 214","GSM405713","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 73","status: 1","fumnd: 5","age: 65","sample nr: 435","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405713/GSM405713.xls.gz","37632"
"GSM405714","Ovarian tumor sample 313","GSM405714","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 127","status: 1","fumnd: 37","age: 44","sample nr: 280","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405714/GSM405714.xls.gz","37632"
"GSM405715","Ovarian tumor sample 314","GSM405715","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 127","status: 1","fumnd: 37","age: 44","sample nr: 280","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405715/GSM405715.xls.gz","37632"
"GSM405716","Ovarian tumor sample 149","GSM405716","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 56","status: 0","fumnd: 133","age: 49","sample nr: 349","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405716/GSM405716.xls.gz","37632"
"GSM405717","Ovarian tumor sample 342","GSM405717","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 136","status: 1","fumnd: 7","age: 40","sample nr: 281","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405717/GSM405717.xls.gz","37632"
"GSM405718","Ovarian tumor sample 5","GSM405718","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 23","status: 0","fumnd: 54","age: 66","sample nr: 401","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405718/GSM405718.xls.gz","37632"
"GSM405719","Ovarian tumor sample 397","GSM405719","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 153","status: 1","fumnd: 13","age: 80","sample nr: 282","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405719/GSM405719.xls.gz","37632"
"GSM405720","Ovarian tumor sample 6","GSM405720","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 23","status: 0","fumnd: 54","age: 66","sample nr: 401","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405720/GSM405720.xls.gz","37632"
"GSM405721","Ovarian tumor sample 398","GSM405721","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 153","status: 1","fumnd: 13","age: 80","sample nr: 282","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405721/GSM405721.xls.gz","37632"
"GSM405722","Ovarian tumor sample 159","GSM405722","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 104","status: 1","fumnd: 49","age: 37","sample nr: 283","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405722/GSM405722.xls.gz","37632"
"GSM405723","Ovarian tumor sample 288","GSM405723","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 118","status: 1","fumnd: 43","age: 42","sample nr: 202","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405723/GSM405723.xls.gz","37632"
"GSM405724","Ovarian tumor sample 248","GSM405724","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 110","status: 1","fumnd: 41","age: 73","sample nr: 285","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405724/GSM405724.xls.gz","37632"
"GSM405725","Ovarian tumor sample 92","GSM405725","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 96","status: 0","fumnd: 58","age: 54","sample nr: 62","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405725/GSM405725.xls.gz","37632"
"GSM405726","Ovarian tumor sample 276","GSM405726","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 115","status: 1","fumnd: 14","age: 60","sample nr: 286","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405726/GSM405726.xls.gz","37632"
"GSM405727","Ovarian tumor sample 364","GSM405727","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 142","status: 1","fumnd: 31","age: 67","sample nr: 289","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405727/GSM405727.xls.gz","37632"
"GSM405728","Ovarian tumor sample 329","GSM405728","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 132","status: 1","fumnd: 16","age: 27","sample nr: 292","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405728/GSM405728.xls.gz","37632"
"GSM405729","Ovarian tumor sample 330","GSM405729","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 132","status: 1","fumnd: 16","age: 27","sample nr: 292","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405729/GSM405729.xls.gz","37632"
"GSM405730","Ovarian tumor sample 263","GSM405730","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 15","status: 1","fumnd: 6","age: 68","sample nr: 371","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405730/GSM405730.xls.gz","37632"
"GSM405731","Ovarian tumor sample 76","GSM405731","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 94","status: 1","fumnd: 167","age: 31","sample nr: 293","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405731/GSM405731.xls.gz","37632"
"GSM405732","Ovarian tumor sample 245","GSM405732","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 12","status: 1","fumnd: 21","age: 67","sample nr: 185","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405732/GSM405732.xls.gz","37632"
"GSM405733","Ovarian tumor sample 17","GSM405733","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 85","status: 1","fumnd: 25","age: 51","sample nr: 296","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405733/GSM405733.xls.gz","37632"
"GSM405734","Ovarian tumor sample 350","GSM405734","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 82","status: 0","fumnd: 45","age: 65","sample nr: 298","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405734/GSM405734.xls.gz","37632"
"GSM405735","Ovarian tumor sample 7","GSM405735","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 23","status: 0","fumnd: 54","age: 66","sample nr: 39","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405735/GSM405735.xls.gz","37632"
"GSM405736","Ovarian tumor sample 40","GSM405736","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 88","status: 1","fumnd: 11","age: 79","sample nr: 299","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405736/GSM405736.xls.gz","37632"
"GSM405737","Ovarian tumor sample 327","GSM405737","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 131","status: 1","fumnd: 33","age: 58","sample nr: 109","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405737/GSM405737.xls.gz","37632"
"GSM405738","Ovarian tumor sample 322","GSM405738","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 129","status: 0","fumnd: 130","age: 69","sample nr: 441","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405738/GSM405738.xls.gz","37632"
"GSM405739","Ovarian tumor sample 324","GSM405739","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 130","status: 1","fumnd: 16","age: 60","sample nr: 420","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405739/GSM405739.xls.gz","37632"
"GSM405740","Ovarian tumor sample 151","GSM405740","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 103","status: 1","fumnd: 20","age: 57","sample nr: 305","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405740/GSM405740.xls.gz","37632"
"GSM405741","Ovarian tumor sample 186","GSM405741","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 66","status: 1","fumnd: 10","age: 75","sample nr: 179","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405741/GSM405741.xls.gz","37632"
"GSM405742","Ovarian tumor sample 224","GSM405742","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 109","status: 1","fumnd: 12","age: 53","sample nr: 307","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405742/GSM405742.xls.gz","37632"
"GSM405743","Ovarian tumor sample 51","GSM405743","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 91","status: 1","fumnd: 13","age: 52","sample nr: 53","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405743/GSM405743.xls.gz","37632"
"GSM405744","Ovarian tumor sample 77","GSM405744","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 94","status: 1","fumnd: 167","age: 31","sample nr: 129","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405744/GSM405744.xls.gz","37632"
"GSM405745","Ovarian tumor sample 99","GSM405745","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 99","status: 0","fumnd: 14","age: 65","sample nr: 130","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405745/GSM405745.xls.gz","37632"
"GSM405746","Ovarian tumor sample 176","GSM405746","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 64","status: 0","fumnd: 53","age: 63","sample nr: 427","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405746/GSM405746.xls.gz","37632"
"GSM405747","Ovarian tumor sample 225","GSM405747","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 109","status: 1","fumnd: 12","age: 53","sample nr: 307","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405747/GSM405747.xls.gz","37632"
"GSM405748","Ovarian tumor sample 226","GSM405748","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 109","status: 1","fumnd: 12","age: 53","sample nr: 307","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405748/GSM405748.xls.gz","37632"
"GSM405749","Ovarian tumor sample 227","GSM405749","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 109","status: 1","fumnd: 12","age: 53","sample nr: 307","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405749/GSM405749.xls.gz","37632"
"GSM405750","Ovarian tumor sample 1","GSM405750","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 21","status: 1","fumnd: 36","age: 66","sample nr: 383","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405750/GSM405750.xls.gz","37632"
"GSM405751","Ovarian tumor sample 375","GSM405751","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 147","status: 1","fumnd: 9","age: 62","sample nr: 323","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405751/GSM405751.xls.gz","37632"
"GSM405752","Ovarian tumor sample 331","GSM405752","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 133","status: 1","fumnd: 22","age: 61","sample nr: 452","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405752/GSM405752.xls.gz","37632"
"GSM405753","Ovarian tumor sample 136","GSM405753","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 53","status: 1","fumnd: 66","age: 60","sample nr: 219","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405753/GSM405753.xls.gz","37632"
"GSM405754","Ovarian tumor sample 217","GSM405754","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 8","status: 1","fumnd: 12","age: 71","sample nr: 327","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405754/GSM405754.xls.gz","37632"
"GSM405755","Ovarian tumor sample 218","GSM405755","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 8","status: 1","fumnd: 12","age: 71","sample nr: 327","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405755/GSM405755.xls.gz","37632"
"GSM405756","Ovarian tumor sample 133","GSM405756","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 52","status: 1","fumnd: 234","age: 26","sample nr: 468","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405756/GSM405756.xls.gz","37632"
"GSM405757","Ovarian tumor sample 210","GSM405757","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 6","status: 0","fumnd: 64","age: 70","sample nr: 376","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405757/GSM405757.xls.gz","37632"
"GSM405758","Ovarian tumor sample 27","GSM405758","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 26","status: 1","fumnd: 61","age: 71","sample nr: 329","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405758/GSM405758.xls.gz","37632"
"GSM405759","Ovarian tumor sample 369","GSM405759","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 144","status: 1","fumnd: 37","age: 48","sample nr: 331","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405759/GSM405759.xls.gz","37632"
"GSM405760","Ovarian tumor sample 382","GSM405760","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 149","status: 0","fumnd: 116","age: 54","sample nr: 332","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405760/GSM405760.xls.gz","37632"
"GSM405761","Ovarian tumor sample 365","GSM405761","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 142","status: 1","fumnd: 31","age: 67","sample nr: 289","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405761/GSM405761.xls.gz","37632"
"GSM405762","Ovarian tumor sample 389","GSM405762","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 150","status: 1","fumnd: 16","age: 44","sample nr: 333","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405762/GSM405762.xls.gz","37632"
"GSM405763","Ovarian tumor sample 47","GSM405763","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 90","status: 1","fumnd: 4","age: 67","sample nr: 436","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405763/GSM405763.xls.gz","37632"
"GSM405764","Ovarian tumor sample 232","GSM405764","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 9","status: 1","fumnd: 18","age: 42","sample nr: 336","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405764/GSM405764.xls.gz","37632"
"GSM405765","Ovarian tumor sample 48","GSM405765","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 90","status: 1","fumnd: 4","age: 67","sample nr: 436","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405765/GSM405765.xls.gz","37632"
"GSM405766","Ovarian tumor sample 233","GSM405766","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 9","status: 1","fumnd: 18","age: 42","sample nr: 336","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405766/GSM405766.xls.gz","37632"
"GSM405767","Ovarian tumor sample 49","GSM405767","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 90","status: 1","fumnd: 4","age: 67","sample nr: 436","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405767/GSM405767.xls.gz","37632"
"GSM405768","Ovarian tumor sample 234","GSM405768","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 9","status: 1","fumnd: 18","age: 42","sample nr: 336","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405768/GSM405768.xls.gz","37632"
"GSM405769","Ovarian tumor sample 155","GSM405769","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 58","status: 0","fumnd: 59","age: 46","sample nr: 455","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405769/GSM405769.xls.gz","37632"
"GSM405770","Ovarian tumor sample 293","GSM405770","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 16","status: 1","fumnd: 15","age: 55","sample nr: 338","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405770/GSM405770.xls.gz","37632"
"GSM405771","Ovarian tumor sample 349","GSM405771","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 81","status: 1","fumnd: 12","age: 52","sample nr: 134","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405771/GSM405771.xls.gz","37632"
"GSM405772","Ovarian tumor sample 316","GSM405772","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 128","status: 1","fumnd: 9","age: 42","sample nr: 33","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405772/GSM405772.xls.gz","37632"
"GSM405773","Ovarian tumor sample 39","GSM405773","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 30","status: 0","fumnd: 62","age: 71","sample nr: 341","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405773/GSM405773.xls.gz","37632"
"GSM405774","Ovarian tumor sample 115","GSM405774","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 46","status: 1","fumnd: 11","age: 56","sample nr: 345","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405774/GSM405774.xls.gz","37632"
"GSM405775","Ovarian tumor sample 60","GSM405775","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 33","status: 1","fumnd: 30","age: 75","sample nr: 342","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405775/GSM405775.xls.gz","37632"
"GSM405776","Ovarian tumor sample 117","GSM405776","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 46","status: 1","fumnd: 11","age: 56","sample nr: 345","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405776/GSM405776.xls.gz","37632"
"GSM405777","Ovarian tumor sample 61","GSM405777","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 33","status: 1","fumnd: 30","age: 75","sample nr: 342","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405777/GSM405777.xls.gz","37632"
"GSM405778","Ovarian tumor sample 116","GSM405778","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 46","status: 1","fumnd: 11","age: 56","sample nr: 345","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405778/GSM405778.xls.gz","37632"
"GSM405779","Ovarian tumor sample 62","GSM405779","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 33","status: 1","fumnd: 30","age: 75","sample nr: 342","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405779/GSM405779.xls.gz","37632"
"GSM405780","Ovarian tumor sample 405","GSM405780","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 155","status: 0","fumnd: 62","age: 48","sample nr: 113","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405780/GSM405780.xls.gz","37632"
"GSM405781","Ovarian tumor sample 113","GSM405781","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 45","status: 0","fumnd: 64","age: 66","sample nr: 343","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405781/GSM405781.xls.gz","37632"
"GSM405782","Ovarian tumor sample 406","GSM405782","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 155","status: 0","fumnd: 62","age: 48","sample nr: 113","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405782/GSM405782.xls.gz","37632"
"GSM405783","Ovarian tumor sample 114","GSM405783","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 45","status: 0","fumnd: 64","age: 66","sample nr: 343","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405783/GSM405783.xls.gz","37632"
"GSM405784","Ovarian tumor sample 104","GSM405784","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 42","status: 1","fumnd: 2","age: 57","sample nr: 170","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405784/GSM405784.xls.gz","37632"
"GSM405785","Ovarian tumor sample 118","GSM405785","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 46","status: 1","fumnd: 11","age: 56","sample nr: 345","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405785/GSM405785.xls.gz","37632"
"GSM405786","Ovarian tumor sample 271","GSM405786","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 114","status: 1","fumnd: 24","age: 74","sample nr: 209","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405786/GSM405786.xls.gz","37632"
"GSM405787","Ovarian tumor sample 125","GSM405787","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 49","status: 1","fumnd: 30","age: 54","sample nr: 346","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405787/GSM405787.xls.gz","37632"
"GSM405788","Ovarian tumor sample 52","GSM405788","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 91","status: 1","fumnd: 13","age: 52","sample nr: 54","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405788/GSM405788.xls.gz","37632"
"GSM405789","Ovarian tumor sample 150","GSM405789","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 56","status: 0","fumnd: 133","age: 49","sample nr: 349","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405789/GSM405789.xls.gz","37632"
"GSM405790","Ovarian tumor sample 360","GSM405790","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 141","status: 1","fumnd: 6","age: 53","sample nr: 3","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405790/GSM405790.xls.gz","37632"
"GSM405791","Ovarian tumor sample 187","GSM405791","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 67","status: 1","fumnd: 4","age: 22","sample nr: 352","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405791/GSM405791.xls.gz","37632"
"GSM405792","Ovarian tumor sample 28","GSM405792","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 26","status: 1","fumnd: 61","age: 71","sample nr: 40","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405792/GSM405792.xls.gz","37632"
"GSM405793","Ovarian tumor sample 29","GSM405793","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 26","status: 1","fumnd: 61","age: 71","sample nr: 40","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405793/GSM405793.xls.gz","37632"
"GSM405794","Ovarian tumor sample 123","GSM405794","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 48","status: 0","fumnd: 73","age: 73","sample nr: 211","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405794/GSM405794.xls.gz","37632"
"GSM405795","Ovarian tumor sample 272","GSM405795","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 114","status: 1","fumnd: 24","age: 74","sample nr: 355","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405795/GSM405795.xls.gz","37632"
"GSM405796","Ovarian tumor sample 373","GSM405796","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 146","status: 1","fumnd: 9","age: 60","sample nr: 226","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405796/GSM405796.xls.gz","37632"
"GSM405797","Ovarian tumor sample 46","GSM405797","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 31","status: 1","fumnd: 10","age: 84","sample nr: 363","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405797/GSM405797.xls.gz","37632"
"GSM405798","Ovarian tumor sample 264","GSM405798","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 15","status: 1","fumnd: 6","age: 68","sample nr: 371","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405798/GSM405798.xls.gz","37632"
"GSM405799","Ovarian tumor sample 292","GSM405799","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 120","status: 1","fumnd: 37","age: 69","sample nr: 374","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405799/GSM405799.xls.gz","37632"
"GSM405800","Ovarian tumor sample 211","GSM405800","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 6","status: 0","fumnd: 64","age: 70","sample nr: 376","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405800/GSM405800.xls.gz","37632"
"GSM405801","Ovarian tumor sample 167","GSM405801","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 61","status: 0","fumnd: 67","age: 72","sample nr: 193","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405801/GSM405801.xls.gz","37632"
"GSM405802","Ovarian tumor sample 219","GSM405802","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 8","status: 1","fumnd: 12","age: 71","sample nr: 377","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405802/GSM405802.xls.gz","37632"
"GSM405803","Ovarian tumor sample 168","GSM405803","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 61","status: 0","fumnd: 67","age: 72","sample nr: 193","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405803/GSM405803.xls.gz","37632"
"GSM405804","Ovarian tumor sample 220","GSM405804","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 8","status: 1","fumnd: 12","age: 71","sample nr: 377","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405804/GSM405804.xls.gz","37632"
"GSM405805","Ovarian tumor sample 120","GSM405805","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 47","status: 1","fumnd: 33","age: 43","sample nr: 379","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405805/GSM405805.xls.gz","37632"
"GSM405806","Ovarian tumor sample 121","GSM405806","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 47","status: 1","fumnd: 33","age: 43","sample nr: 379","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405806/GSM405806.xls.gz","37632"
"GSM405807","Ovarian tumor sample 237","GSM405807","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 75","status: 1","fumnd: 13","age: 58","sample nr: 438","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405807/GSM405807.xls.gz","37632"
"GSM405808","Ovarian tumor sample 238","GSM405808","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 75","status: 1","fumnd: 13","age: 58","sample nr: 438","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405808/GSM405808.xls.gz","37632"
"GSM405809","Ovarian tumor sample 160","GSM405809","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 104","status: 1","fumnd: 49","age: 37","sample nr: 283","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405809/GSM405809.xls.gz","37632"
"GSM405810","Ovarian tumor sample 2","GSM405810","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 21","status: 1","fumnd: 36","age: 66","sample nr: 383","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405810/GSM405810.xls.gz","37632"
"GSM405811","Ovarian tumor sample 319","GSM405811","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 80","status: 1","fumnd: 47","age: 50","sample nr: 233","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405811/GSM405811.xls.gz","37632"
"GSM405812","Ovarian tumor sample 401","GSM405812","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 154","status: 1","fumnd: 21","age: 55","sample nr: 384","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405812/GSM405812.xls.gz","37632"
"GSM405813","Ovarian tumor sample 320","GSM405813","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 80","status: 1","fumnd: 47","age: 50","sample nr: 233","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405813/GSM405813.xls.gz","37632"
"GSM405814","Ovarian tumor sample 402","GSM405814","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 154","status: 1","fumnd: 21","age: 55","sample nr: 384","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405814/GSM405814.xls.gz","37632"
"GSM405815","Ovarian tumor sample 321","GSM405815","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 80","status: 1","fumnd: 47","age: 50","sample nr: 233","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405815/GSM405815.xls.gz","37632"
"GSM405816","Ovarian tumor sample 403","GSM405816","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 154","status: 1","fumnd: 21","age: 55","sample nr: 384","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405816/GSM405816.xls.gz","37632"
"GSM405817","Ovarian tumor sample 145","GSM405817","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 54","status: 0","fumnd: 2","age: 71","sample nr: 385","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405817/GSM405817.xls.gz","37632"
"GSM405818","Ovarian tumor sample 317","GSM405818","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 128","status: 1","fumnd: 9","age: 42","sample nr: 33","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405818/GSM405818.xls.gz","37632"
"GSM405819","Ovarian tumor sample 146","GSM405819","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 54","status: 0","fumnd: 2","age: 71","sample nr: 385","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405819/GSM405819.xls.gz","37632"
"GSM405820","Ovarian tumor sample 310","GSM405820","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 125","status: 0","fumnd: 71","age: 66","sample nr: 167","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405820/GSM405820.xls.gz","37632"
"GSM405821","Ovarian tumor sample 193","GSM405821","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 70","status: 1","fumnd: 17","age: 62","sample nr: 395","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405821/GSM405821.xls.gz","37632"
"GSM405822","Ovarian tumor sample 153","GSM405822","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 57","status: 1","fumnd: 20","age: 71","sample nr: 392","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405822/GSM405822.xls.gz","37632"
"GSM405823","Ovarian tumor sample 194","GSM405823","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 70","status: 1","fumnd: 17","age: 62","sample nr: 395","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405823/GSM405823.xls.gz","37632"
"GSM405824","Ovarian tumor sample 154","GSM405824","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 57","status: 1","fumnd: 20","age: 71","sample nr: 392","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405824/GSM405824.xls.gz","37632"
"GSM405825","Ovarian tumor sample 338","GSM405825","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 135","status: 1","fumnd: 15","age: 62","sample nr: 207","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405825/GSM405825.xls.gz","37632"
"GSM405826","Ovarian tumor sample 161","GSM405826","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 60","status: 1","fumnd: 28","age: 66","sample nr: 393","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405826/GSM405826.xls.gz","37632"
"GSM405827","Ovarian tumor sample 182","GSM405827","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 65","status: 1","fumnd: 70","age: 61","sample nr: 394","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405827/GSM405827.xls.gz","37632"
"GSM405828","Ovarian tumor sample 183","GSM405828","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 65","status: 1","fumnd: 70","age: 61","sample nr: 394","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405828/GSM405828.xls.gz","37632"
"GSM405829","Ovarian tumor sample 260","GSM405829","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 13","status: 1","fumnd: 19","age: 41","sample nr: 259","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405829/GSM405829.xls.gz","37632"
"GSM405830","Ovarian tumor sample 195","GSM405830","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 70","status: 1","fumnd: 17","age: 62","sample nr: 395","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405830/GSM405830.xls.gz","37632"
"GSM405831","Ovarian tumor sample 4","GSM405831","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 22","status: 0","fumnd: 65","age: 63","sample nr: 261","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405831/GSM405831.xls.gz","37632"
"GSM405832","Ovarian tumor sample 229","GSM405832","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 74","status: 1","fumnd: 12","age: 64","sample nr: 396","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405832/GSM405832.xls.gz","37632"
"GSM405833","Ovarian tumor sample 409","GSM405833","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 157","status: 0","fumnd: 37","age: 57","sample nr: 72","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405833/GSM405833.xls.gz","37632"
"GSM405834","Ovarian tumor sample 305","GSM405834","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 123","status: 1","fumnd: 59","age: 42","sample nr: 116","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405834/GSM405834.xls.gz","37632"
"GSM405835","Ovarian tumor sample 8","GSM405835","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 23","status: 0","fumnd: 54","age: 66","sample nr: 39","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405835/GSM405835.xls.gz","37632"
"GSM405836","Ovarian tumor sample 394","GSM405836","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 152","status: 0","fumnd: 84","age: 42","sample nr: 430","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405836/GSM405836.xls.gz","37632"
"GSM405837","Ovarian tumor sample 358","GSM405837","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 141","status: 1","fumnd: 6","age: 53","sample nr: 3","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405837/GSM405837.xls.gz","37632"
"GSM405838","Ovarian tumor sample 395","GSM405838","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 152","status: 0","fumnd: 84","age: 42","sample nr: 430","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405838/GSM405838.xls.gz","37632"
"GSM405839","Ovarian tumor sample 359","GSM405839","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 141","status: 1","fumnd: 6","age: 53","sample nr: 3","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405839/GSM405839.xls.gz","37632"
"GSM405840","Ovarian tumor sample 384","GSM405840","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 19","status: 1","fumnd: 14","age: 74","sample nr: 400","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405840/GSM405840.xls.gz","37632"
"GSM405841","Ovarian tumor sample 408","GSM405841","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 156","status: 0","fumnd: 77","age: 46","sample nr: 231","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405841/GSM405841.xls.gz","37632"
"GSM405842","Ovarian tumor sample 9","GSM405842","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 23","status: 0","fumnd: 54","age: 66","sample nr: 401","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405842/GSM405842.xls.gz","37632"
"GSM405843","Ovarian tumor sample 184","GSM405843","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 65","status: 1","fumnd: 70","age: 61","sample nr: 394","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405843/GSM405843.xls.gz","37632"
"GSM405844","Ovarian tumor sample 107","GSM405844","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 43","status: 0","fumnd: 59","age: 63","sample nr: 402","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405844/GSM405844.xls.gz","37632"
"GSM405845","Ovarian tumor sample 335","GSM405845","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 134","status: 1","fumnd: 2","age: 51","sample nr: 408","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405845/GSM405845.xls.gz","37632"
"GSM405846","Ovarian tumor sample 72","GSM405846","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 35","status: 1","fumnd: 62","age: 72","sample nr: 409","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405846/GSM405846.xls.gz","37632"
"GSM405847","Ovarian tumor sample 30","GSM405847","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 26","status: 1","fumnd: 61","age: 71","sample nr: 40","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405847/GSM405847.xls.gz","37632"
"GSM405848","Ovarian tumor sample 31","GSM405848","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 26","status: 1","fumnd: 61","age: 71","sample nr: 40","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405848/GSM405848.xls.gz","37632"
"GSM405849","Ovarian tumor sample 315","GSM405849","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 127","status: 1","fumnd: 37","age: 44","sample nr: 280","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405849/GSM405849.xls.gz","37632"
"GSM405850","Ovarian tumor sample 294","GSM405850","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 16","status: 1","fumnd: 15","age: 55","sample nr: 338","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405850/GSM405850.xls.gz","37632"
"GSM405851","Ovarian tumor sample 295","GSM405851","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 16","status: 1","fumnd: 15","age: 55","sample nr: 338","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405851/GSM405851.xls.gz","37632"
"GSM405852","Ovarian tumor sample 199","GSM405852","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 3","status: 1","fumnd: 47","age: 55","sample nr: 413","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405852/GSM405852.xls.gz","37632"
"GSM405853","Ovarian tumor sample 249","GSM405853","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 110","status: 1","fumnd: 41","age: 73","sample nr: 285","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405853/GSM405853.xls.gz","37632"
"GSM405854","Ovarian tumor sample 341","GSM405854","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 18","status: 0","fumnd: 136","age: 60","sample nr: 415","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405854/GSM405854.xls.gz","37632"
"GSM405855","Ovarian tumor sample 376","GSM405855","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 147","status: 1","fumnd: 9","age: 62","sample nr: 323","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405855/GSM405855.xls.gz","37632"
"GSM405856","Ovarian tumor sample 223","GSM405856","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 108","status: 1","fumnd: 22","age: 61","sample nr: 419","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405856/GSM405856.xls.gz","37632"
"GSM405857","Ovarian tumor sample 206","GSM405857","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 5","status: 1","fumnd: 7","age: 40","sample nr: 458","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405857/GSM405857.xls.gz","37632"
"GSM405858","Ovarian tumor sample 325","GSM405858","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 130","status: 1","fumnd: 16","age: 60","sample nr: 420","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405858/GSM405858.xls.gz","37632"
"GSM405859","Ovarian tumor sample 280","GSM405859","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 116","status: 0","fumnd: 117","age: 52","sample nr: 472","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405859/GSM405859.xls.gz","37632"
"GSM405860","Ovarian tumor sample 298","GSM405860","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 17","status: 1","fumnd: 2","age: 70","sample nr: 422","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405860/GSM405860.xls.gz","37632"
"GSM405861","Ovarian tumor sample 387","GSM405861","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 20","status: 1","fumnd: 46","age: 71","sample nr: 423","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405861/GSM405861.xls.gz","37632"
"GSM405862","Ovarian tumor sample 35","GSM405862","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 28","status: 1","fumnd: 42","age: 68","sample nr: 425","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405862/GSM405862.xls.gz","37632"
"GSM405863","Ovarian tumor sample 262","GSM405863","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 14","status: 1","fumnd: 9","age: 60","sample nr: 239","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405863/GSM405863.xls.gz","37632"
"GSM405864","Ovarian tumor sample 177","GSM405864","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 64","status: 0","fumnd: 53","age: 63","sample nr: 427","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405864/GSM405864.xls.gz","37632"
"GSM405865","Ovarian tumor sample 163","GSM405865","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 105","status: 0","fumnd: 59","age: 65","sample nr: 471","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405865/GSM405865.xls.gz","37632"
"GSM405866","Ovarian tumor sample 172","GSM405866","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 106","status: 1","fumnd: 12","age: 49","sample nr: 429","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405866/GSM405866.xls.gz","37632"
"GSM405867","Ovarian tumor sample 396","GSM405867","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 152","status: 0","fumnd: 84","age: 42","sample nr: 430","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405867/GSM405867.xls.gz","37632"
"GSM405868","Ovarian tumor sample 190","GSM405868","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 68","status: 1","fumnd: 30","age: 72","sample nr: 431","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405868/GSM405868.xls.gz","37632"
"GSM405869","Ovarian tumor sample 301","GSM405869","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 122","status: 1","fumnd: 50","age: 53","sample nr: 95","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405869/GSM405869.xls.gz","37632"
"GSM405870","Ovarian tumor sample 336","GSM405870","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 134","status: 1","fumnd: 2","age: 51","sample nr: 408","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405870/GSM405870.xls.gz","37632"
"GSM405871","Ovarian tumor sample 158","GSM405871","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 59","status: 1","fumnd: 2","age: 45","sample nr: 263","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405871/GSM405871.xls.gz","37632"
"GSM405872","Ovarian tumor sample 215","GSM405872","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 73","status: 1","fumnd: 5","age: 65","sample nr: 435","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405872/GSM405872.xls.gz","37632"
"GSM405873","Ovarian tumor sample 50","GSM405873","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 90","status: 1","fumnd: 4","age: 67","sample nr: 436","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405873/GSM405873.xls.gz","37632"
"GSM405874","Ovarian tumor sample 101","GSM405874","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 41","status: 0","fumnd: 25","age: 54","sample nr: 197","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405874/GSM405874.xls.gz","37632"
"GSM405875","Ovarian tumor sample 239","GSM405875","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 75","status: 1","fumnd: 13","age: 58","sample nr: 438","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405875/GSM405875.xls.gz","37632"
"GSM405876","Ovarian tumor sample 102","GSM405876","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 41","status: 0","fumnd: 25","age: 54","sample nr: 197","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405876/GSM405876.xls.gz","37632"
"GSM405877","Ovarian tumor sample 240","GSM405877","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 75","status: 1","fumnd: 13","age: 58","sample nr: 438","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405877/GSM405877.xls.gz","37632"
"GSM405878","Ovarian tumor sample 188","GSM405878","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 67","status: 1","fumnd: 4","age: 22","sample nr: 352","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405878/GSM405878.xls.gz","37632"
"GSM405879","Ovarian tumor sample 279","GSM405879","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 79","status: 1","fumnd: 16","age: 39","sample nr: 439","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405879/GSM405879.xls.gz","37632"
"GSM405880","Ovarian tumor sample 143","GSM405880","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 102","status: 0","fumnd: 132","age: 65","sample nr: 43","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405880/GSM405880.xls.gz","37632"
"GSM405881","Ovarian tumor sample 302","GSM405881","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 122","status: 1","fumnd: 50","age: 53","sample nr: 112","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405881/GSM405881.xls.gz","37632"
"GSM405882","Ovarian tumor sample 178","GSM405882","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 107","status: 0","fumnd: 119","age: 21","sample nr: 440","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405882/GSM405882.xls.gz","37632"
"GSM405883","Ovarian tumor sample 323","GSM405883","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 129","status: 0","fumnd: 130","age: 69","sample nr: 441","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405883/GSM405883.xls.gz","37632"
"GSM405884","Ovarian tumor sample 144","GSM405884","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 102","status: 0","fumnd: 132","age: 65","sample nr: 43","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405884/GSM405884.xls.gz","37632"
"GSM405885","Ovarian tumor sample 413","GSM405885","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 84","status: 1","fumnd: 8","age: 66","sample nr: 442","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405885/GSM405885.xls.gz","37632"
"GSM405886","Ovarian tumor sample 367","GSM405886","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 143","status: 1","fumnd: 32","age: 43","sample nr: 444","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405886/GSM405886.xls.gz","37632"
"GSM405887","Ovarian tumor sample 130","GSM405887","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 1","status: 1","fumnd: 41","age: 55","sample nr: 200","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405887/GSM405887.xls.gz","37632"
"GSM405888","Ovarian tumor sample 57","GSM405888","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 32","status: 1","fumnd: 27","age: 57","sample nr: 461","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405888/GSM405888.xls.gz","37632"
"GSM405889","Ovarian tumor sample 221","GSM405889","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 8","status: 1","fumnd: 12","age: 71","sample nr: 327","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405889/GSM405889.xls.gz","37632"
"GSM405890","Ovarian tumor sample 139","GSM405890","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 101","status: 1","fumnd: 42","age: 57","sample nr: 450","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405890/GSM405890.xls.gz","37632"
"GSM405891","Ovarian tumor sample 347","GSM405891","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 138","status: 1","fumnd: 12","age: 63","sample nr: 182","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405891/GSM405891.xls.gz","37632"
"GSM405892","Ovarian tumor sample 332","GSM405892","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 133","status: 1","fumnd: 22","age: 61","sample nr: 451","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405892/GSM405892.xls.gz","37632"
"GSM405893","Ovarian tumor sample 351","GSM405893","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 82","status: 0","fumnd: 45","age: 65","sample nr: 298","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405893/GSM405893.xls.gz","37632"
"GSM405894","Ovarian tumor sample 333","GSM405894","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 133","status: 1","fumnd: 22","age: 61","sample nr: 452","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405894/GSM405894.xls.gz","37632"
"GSM405895","Ovarian tumor sample 79","GSM405895","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 36","status: 1","fumnd: 12","age: 71","sample nr: 184","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405895/GSM405895.xls.gz","37632"
"GSM405896","Ovarian tumor sample 399","GSM405896","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 153","status: 1","fumnd: 13","age: 80","sample nr: 282","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405896/GSM405896.xls.gz","37632"
"GSM405897","Ovarian tumor sample 393","GSM405897","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 151","status: 1","fumnd: 13","age: 51","sample nr: 104","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405897/GSM405897.xls.gz","37632"
"GSM405898","Ovarian tumor sample 156","GSM405898","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 58","status: 0","fumnd: 59","age: 46","sample nr: 455","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405898/GSM405898.xls.gz","37632"
"GSM405899","Ovarian tumor sample 250","GSM405899","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 77","status: 1","fumnd: 11","age: 25","sample nr: 51","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405899/GSM405899.xls.gz","37632"
"GSM405900","Ovarian tumor sample 197","GSM405900","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 2","status: 1","fumnd: 1","age: 64","sample nr: 457","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405900/GSM405900.xls.gz","37632"
"GSM405901","Ovarian tumor sample 207","GSM405901","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 5","status: 1","fumnd: 7","age: 40","sample nr: 458","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405901/GSM405901.xls.gz","37632"
"GSM405902","Ovarian tumor sample 10","GSM405902","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 24","status: 0","fumnd: 5","age: 52","sample nr: 459","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405902/GSM405902.xls.gz","37632"
"GSM405903","Ovarian tumor sample 11","GSM405903","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 24","status: 0","fumnd: 5","age: 52","sample nr: 459","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405903/GSM405903.xls.gz","37632"
"GSM405904","Ovarian tumor sample 148","GSM405904","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 55","status: 1","fumnd: 12","age: 65","sample nr: 190","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405904/GSM405904.xls.gz","37632"
"GSM405905","Ovarian tumor sample 356","GSM405905","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 140","status: 0","fumnd: 124","age: 74","sample nr: 45","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405905/GSM405905.xls.gz","37632"
"GSM405906","Ovarian tumor sample 37","GSM405906","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 29","status: 1","fumnd: 16","age: 72","sample nr: 460","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405906/GSM405906.xls.gz","37632"
"GSM405907","Ovarian tumor sample 85","GSM405907","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 39","status: 1","fumnd: 5","age: 76","sample nr: 165","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405907/GSM405907.xls.gz","37632"
"GSM405908","Ovarian tumor sample 58","GSM405908","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 32","status: 1","fumnd: 27","age: 57","sample nr: 461","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405908/GSM405908.xls.gz","37632"
"GSM405909","Ovarian tumor sample 71","GSM405909","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 34","status: 0","fumnd: 122","age: 42","sample nr: 463","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405909/GSM405909.xls.gz","37632"
"GSM405910","Ovarian tumor sample 290","GSM405910","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 119","status: 1","fumnd: 12","age: 57","sample nr: 183","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405910/GSM405910.xls.gz","37632"
"GSM405911","Ovarian tumor sample 81","GSM405911","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 37","status: 1","fumnd: 68","age: 48","sample nr: 194","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405911/GSM405911.xls.gz","37632"
"GSM405912","Ovarian tumor sample 83","GSM405912","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 38","status: 0","fumnd: 14","age: 80","sample nr: 466","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405912/GSM405912.xls.gz","37632"
"GSM405913","Ovarian tumor sample 179","GSM405913","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 107","status: 0","fumnd: 119","age: 21","sample nr: 440","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405913/GSM405913.xls.gz","37632"
"GSM405914","Ovarian tumor sample 134","GSM405914","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 52","status: 1","fumnd: 234","age: 26","sample nr: 468","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405914/GSM405914.xls.gz","37632"
"GSM405915","Ovarian tumor sample 343","GSM405915","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 136","status: 1","fumnd: 7","age: 40","sample nr: 281","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405915/GSM405915.xls.gz","37632"
"GSM405916","Ovarian tumor sample 164","GSM405916","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 105","status: 0","fumnd: 59","age: 65","sample nr: 471","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405916/GSM405916.xls.gz","37632"
"GSM405917","Ovarian tumor sample 281","GSM405917","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 116","status: 0","fumnd: 117","age: 52","sample nr: 472","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405917/GSM405917.xls.gz","37632"
"GSM405918","Ovarian tumor sample 362","GSM405918","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 83","status: 0","fumnd: 43","age: 66","sample nr: 244","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405918/GSM405918.xls.gz","37632"
"GSM405919","Ovarian tumor sample 363","GSM405919","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 83","status: 0","fumnd: 43","age: 66","sample nr: 244","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405919/GSM405919.xls.gz","37632"
"GSM405920","Ovarian tumor sample 334","GSM405920","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 133","status: 1","fumnd: 22","age: 61","sample nr: 451","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405920/GSM405920.xls.gz","37632"
"GSM405921","Ovarian tumor sample 299","GSM405921","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 17","status: 1","fumnd: 2","age: 70","sample nr: 422","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405921/GSM405921.xls.gz","37632"
"GSM405922","Ovarian tumor sample 414","GSM405922","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 84","status: 1","fumnd: 8","age: 66","sample nr: 442","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405922/GSM405922.xls.gz","37632"
"GSM405923","Ovarian tumor sample 415","GSM405923","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 84","status: 1","fumnd: 8","age: 66","sample nr: 442","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405923/GSM405923.xls.gz","37632"
"GSM405924","Ovarian tumor sample 95","GSM405924","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 97","status: 1","fumnd: 9","age: 74","sample nr: 482","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405924/GSM405924.xls.gz","37632"
"GSM405925","Ovarian tumor sample 12","GSM405925","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 24","status: 0","fumnd: 5","age: 52","sample nr: 459","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405925/GSM405925.xls.gz","37632"
"GSM405926","Ovarian tumor sample 251","GSM405926","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 77","status: 1","fumnd: 11","age: 25","sample nr: 52","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405926/GSM405926.xls.gz","37632"
"GSM405927","Ovarian tumor sample 345","GSM405927","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 137","status: 1","fumnd: 30","age: 50","sample nr: 15","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405927/GSM405927.xls.gz","37632"
"GSM405928","Ovarian tumor sample 242","GSM405928","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 11","status: 1","fumnd: 5","age: 48","sample nr: 173","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405928/GSM405928.xls.gz","37632"
"GSM405929","Ovarian tumor sample 243","GSM405929","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 11","status: 1","fumnd: 5","age: 48","sample nr: 173","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405929/GSM405929.xls.gz","37632"
"GSM405930","Ovarian tumor sample 162","GSM405930","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 60","status: 1","fumnd: 28","age: 66","sample nr: 393","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405930/GSM405930.xls.gz","37632"
"GSM405931","Ovarian tumor sample 357","GSM405931","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 140","status: 0","fumnd: 124","age: 74","sample nr: 48","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405931/GSM405931.xls.gz","37632"
"GSM405932","Ovarian tumor sample 252","GSM405932","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 77","status: 1","fumnd: 11","age: 25","sample nr: 51","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405932/GSM405932.xls.gz","37632"
"GSM405933","Ovarian tumor sample 253","GSM405933","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 77","status: 1","fumnd: 11","age: 25","sample nr: 52","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405933/GSM405933.xls.gz","37632"
"GSM405934","Ovarian tumor sample 53","GSM405934","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 91","status: 1","fumnd: 13","age: 52","sample nr: 53","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405934/GSM405934.xls.gz","37632"
"GSM405935","Ovarian tumor sample 213","GSM405935","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 7","status: 1","fumnd: 17","age: 72","sample nr: 262","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405935/GSM405935.xls.gz","37632"
"GSM405936","Ovarian tumor sample 54","GSM405936","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 91","status: 1","fumnd: 13","age: 52","sample nr: 54","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405936/GSM405936.xls.gz","37632"
"GSM405937","Ovarian tumor sample 140","GSM405937","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 101","status: 1","fumnd: 42","age: 57","sample nr: 450","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405937/GSM405937.xls.gz","37632"
"GSM405938","Ovarian tumor sample 64","GSM405938","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 92","status: 0","fumnd: 20","age: 45","sample nr: 55","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405938/GSM405938.xls.gz","37632"
"GSM405939","Ovarian tumor sample 377","GSM405939","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 147","status: 1","fumnd: 9","age: 62","sample nr: 227","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405939/GSM405939.xls.gz","37632"
"GSM405940","Ovarian tumor sample 65","GSM405940","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 92","status: 0","fumnd: 20","age: 45","sample nr: 56","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405940/GSM405940.xls.gz","37632"
"GSM405941","Ovarian tumor sample 43","GSM405941","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 89","status: 1","fumnd: 11","age: 68","sample nr: 237","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405941/GSM405941.xls.gz","37632"
"GSM405942","Ovarian tumor sample 44","GSM405942","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 89","status: 1","fumnd: 11","age: 68","sample nr: 237","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405942/GSM405942.xls.gz","37632"
"GSM405943","Ovarian tumor sample 109","GSM405943","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 44","status: 1","fumnd: 16","age: 66","sample nr: 5","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405943/GSM405943.xls.gz","37632"
"GSM405944","Ovarian tumor sample 110","GSM405944","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 44","status: 1","fumnd: 16","age: 66","sample nr: 5","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405944/GSM405944.xls.gz","37632"
"GSM405945","Ovarian tumor sample 55","GSM405945","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 91","status: 1","fumnd: 13","age: 52","sample nr: 65","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405945/GSM405945.xls.gz","37632"
"GSM405946","Ovarian tumor sample 138","GSM405946","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 100","status: 1","fumnd: 18","age: 62","sample nr: 61","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405946/GSM405946.xls.gz","37632"
"GSM405947","Ovarian tumor sample 277","GSM405947","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 115","status: 1","fumnd: 14","age: 60","sample nr: 286","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405947/GSM405947.xls.gz","37632"
"GSM405948","Ovarian tumor sample 93","GSM405948","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 96","status: 0","fumnd: 58","age: 54","sample nr: 62","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405948/GSM405948.xls.gz","37632"
"GSM405949","Ovarian tumor sample 306","GSM405949","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 124","status: 1","fumnd: 19","age: 48","sample nr: 7","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405949/GSM405949.xls.gz","37632"
"GSM405950","Ovarian tumor sample 91","GSM405950","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 95","status: 0","fumnd: 6","age: 71","sample nr: 63","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405950/GSM405950.xls.gz","37632"
"GSM405951","Ovarian tumor sample 266","GSM405951","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 112","status: 0","fumnd: 92","age: 51","sample nr: 168","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405951/GSM405951.xls.gz","37632"
"GSM405952","Ovarian tumor sample 56","GSM405952","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 91","status: 1","fumnd: 13","age: 52","sample nr: 65","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405952/GSM405952.xls.gz","37632"
"GSM405953","Ovarian tumor sample 41","GSM405953","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 88","status: 1","fumnd: 11","age: 79","sample nr: 299","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405953/GSM405953.xls.gz","37632"
"GSM405954","Ovarian tumor sample 25","GSM405954","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 87","status: 1","fumnd: 19","age: 66","sample nr: 67","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405954/GSM405954.xls.gz","37632"
"GSM405955","Ovarian tumor sample 410","GSM405955","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 157","status: 0","fumnd: 37","age: 57","sample nr: 73","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405955/GSM405955.xls.gz","37632"
"GSM405956","Ovarian tumor sample 411","GSM405956","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 157","status: 0","fumnd: 37","age: 57","sample nr: 72","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405956/GSM405956.xls.gz","37632"
"GSM405957","Ovarian tumor sample 97","GSM405957","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 98","status: 0","fumnd: 21","age: 47","sample nr: 136","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405957/GSM405957.xls.gz","37632"
"GSM405958","Ovarian tumor sample 412","GSM405958","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 157","status: 0","fumnd: 37","age: 57","sample nr: 73","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405958/GSM405958.xls.gz","37632"
"GSM405959","Ovarian tumor sample 174","GSM405959","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 63","status: 1","fumnd: 16","age: 51","sample nr: 213","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405959/GSM405959.xls.gz","37632"
"GSM405960","Ovarian tumor sample 307","GSM405960","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 124","status: 1","fumnd: 19","age: 48","sample nr: 7","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405960/GSM405960.xls.gz","37632"
"GSM405961","Ovarian tumor sample 175","GSM405961","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 63","status: 1","fumnd: 16","age: 51","sample nr: 213","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405961/GSM405961.xls.gz","37632"
"GSM405962","Ovarian tumor sample 308","GSM405962","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 124","status: 1","fumnd: 19","age: 48","sample nr: 7","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405962/GSM405962.xls.gz","37632"
"GSM405963","Ovarian tumor sample 66","GSM405963","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 92","status: 0","fumnd: 20","age: 45","sample nr: 55","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405963/GSM405963.xls.gz","37632"
"GSM405964","Ovarian tumor sample 67","GSM405964","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 93","status: 1","fumnd: 83","age: 70","sample nr: 92","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405964/GSM405964.xls.gz","37632"
"GSM405965","Ovarian tumor sample 303","GSM405965","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 122","status: 1","fumnd: 50","age: 53","sample nr: 95","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405965/GSM405965.xls.gz","37632"
"GSM405966","Ovarian tumor sample 73","GSM405966","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 35","status: 1","fumnd: 62","age: 72","sample nr: 409","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405966/GSM405966.xls.gz","37632"
"GSM405967","Ovarian tumor sample 68","GSM405967","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 93","status: 1","fumnd: 83","age: 70","sample nr: 92","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405967/GSM405967.xls.gz","37632"
"GSM405968","Ovarian tumor sample 69","GSM405968","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 93","status: 1","fumnd: 83","age: 70","sample nr: 92","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405968/GSM405968.xls.gz","37632"
"GSM405969","Ovarian tumor sample 33","GSM405969","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 27","status: 0","fumnd: 29","age: 43","sample nr: 254","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy5","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405969/GSM405969.xls.gz","37632"
"GSM405970","Ovarian tumor sample 380","GSM405970","Public on May 20 2009","May 19 2009","May 20 2009","RNA","1","Advanced stage serous ovarian cancer","Homo sapiens","assigned unique patient id: 148","status: 1","fumnd: 10","age: 61","sample nr: 9","All tumor samples were obtained at primary surgery prior to chemotherapy.","All tumor samples were flash frozen in liquid nitrogen and stored at -80 °C.","total RNA","Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.","Cy3","All cRNA samples (1.5 µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKÉ, Leiden, the Netherlands).","9606","Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf","Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).","Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ;  1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number","raw data","GPL7759","Rudolf,Stephan Nicolaas,Fehrmann","r.s.n.fehrmann@og.umcg.nl","Gynecologic Oncology","University Medical Center Groningen","P.O. Box 30.001","Groningen","Groningen","9700 RB","Netherlands","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405970/GSM405970.xls.gz","37632"
